Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3M | 2M | 1M | 70M | 3M |
| Gross Profit | 3M | 2M | 1M | 69M | 1M |
| Operating Income | -4M | -5M | -9M | 1M | -80M |
| EBITDA | -3M | -3M | -8M | 12M | -71M |
| Net Income | -569K | -2M | -10M | 112M | -172M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$2.27
-0.87% today
1Y Change
+104.50%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TherapeuticsMD, Inc. (TXMD) is a Healthcare stock with a market cap of $20.00M and listed on NASDAQ. The stock last traded around $2.27 and up 104.5% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +71.6%, EPS growth of +74.1%, a dividend yield of 0.0%. What stands out right now is revenue +71.6%, EPS +74.1%, free cash flow +235.2% with operating margin -128.8% and ROIC -11.8%. Valuation sits in the middle of the pack at price/sales 7.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TXMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TXMD
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TXMD Max Drawdown
-34.30%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TXMD and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.6M
-96.3% YoY
FY Net Income
-$172.4M
-253.9% YoY
Free Cash Flow
-$147.8M
-3235.1% YoY
Revenue Growth
+71.6%
EPS Growth
+74.1%
Gross Margin
70.0%
Net Margin
-18.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3M | 2M | 1M | 70M | 3M |
| Gross Profit | 3M | 2M | 1M | 69M | 1M |
| Operating Income | -4M | -5M | -9M | 1M | -80M |
| EBITDA | -3M | -3M | -8M | 12M | -71M |
| Net Income | -569K | -2M | -10M | 112M | -172M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 7M | 5M | 4M | 38M | 65M |
| Total Assets | 38M | 39M | 43M | 90M | 169M |
| Total Liabilities | 11M | 11M | 14M | 55M | 263M |
| Shareholder Equity | 27M | 27M | 29M | 35M | -94M |
| Total Debt | 5M | 7M | 8M | 9M | 198M |
| Net Debt | -2M | 2M | 4M | -29M | 133M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
148M
-3524.6% YoY
Capital Expenditures
34K
+90.4% YoY
Free Cash Flow
148M
-3235.1% YoY
Key ratios
Gross Margin
70.0%
Operating Margin
-128.8%
Net Margin
-18.8%
ROE
-2.1%
Debt / Equity
0.19x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.